Anti-RAP1A + RAP1B Monoclonal Antibody for WB, IF/ICC, ELISA - P61224 / P62834

Core Product Specifications and Parameters

Biological Background: RAP1A and RAP1B Function and Localization

• RAP1B is a Ras-related small GTPase that cycles between GDP-bound inactive and GTP-bound active states, mediating intracellular signal transduction.
• It is essential for endothelial cell polarity and vascular lumen formation by regulating the localization of KRIT1, CDH5, PRKCZ, PARD3, and TIAM1.
• RAP1B localizes to the cell membrane, cytoplasm, cytosol, and cell junctions, consistent with its role in cell adhesion and barrier function.
• The protein undergoes multiple post-translational modifications, including prenylation for membrane anchoring, phosphorylation, and methylation.
• RAP1B is highly homologous to RAP1A; this antibody recognizes both human RAP1A and RAP1B.
• Mutations in RAP1B are associated with disease variants, indicating its importance in human pathology.

Experimental Guidance and Technical Tips

• This recombinant rabbit monoclonal antibody was raised against a peptide spanning amino acids 70-150 of human RAP1A and RAP1B. Due to sequence homology, cross-reactivity between the two isoforms is expected.
• For Western blotting, a band of approximately 21 kDa is typically observed; consider using positive control lysates from human, mouse, or rat endothelial cell lines.
• For immunofluorescence/ICC, optimize fixation and permeabilization conditions to preserve junctional staining patterns.
• In ELISA applications, the antibody can be used for both direct and indirect detection; validate coating and blocking conditions empirically.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio serves as a comprehensive raw material partner for IVD manufacturers, research institutes, and diagnostic labs seeking one-stop access to high-quality reagents. This anti-RAP1A+RAP1B antibody is part of our extensive portfolio supporting vascular biology and cell adhesion research. Beyond individual antibodies, we offer validated antibody pairs, bulk ancillary reagents, and custom sourcing for rare targets—streamlining your pipeline from concept to clinic.